Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects With Genetically Confirmed Barth Syndrome Followed by an Open-Label Treatment Extension

Next Previous
Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects With Genetically Confirmed Barth Syndrome Followed by an Open-Label Treatment Extension

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 14 Nov 2018

At a glance

  • Drugs Elamipretide (Primary)
  • Indications Barth syndrome
  • Focus Therapeutic Use
  • Acronyms TAZPOWER
  • Sponsors Stealth BioTherapeutics

    • Most Recent Events

    • 14 Nov 2018 Results presented at the 91st Annual Scientific Sessions of the American Heart Association
    • 04 Oct 2018 Planned End Date changed from 1 Oct 2018 to 1 Dec 2019.
    • 04 Oct 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top